Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study.

Umar Jahangir, Asim Ali Khan, Prem Kapoor, Farhan Jalees, Shaista Urooj
Author Information
  1. Umar Jahangir: Department of Moalejat (Medicine), Faculty of Medicine (U), Jamia Hamdard, New Delhi, India.
  2. Asim Ali Khan: Department of Moalejat (Medicine), Faculty of Medicine (U), Jamia Hamdard, New Delhi, India.
  3. Prem Kapoor: Department of Medicine, Hamdard Institute of Medical Sciences and Research, New Delhi, India.
  4. Farhan Jalees: Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India.
  5. Shaista Urooj: Department of AYUSH, LRIUM, CCRUM, Hamdard Nagar, New Delhi, India.

Abstract

AIM OF THE STUDY: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters.
MATERIALS AND METHODS: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group 'A' thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group 'B' thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group 'C' 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters.
RESULTS: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well.

Keywords

References

  1. Am Rev Respir Dis. 1991 Jan;143(1):9-18 [PMID: 1986689]
  2. J Basic Clin Physiol Pharmacol. 2009;20(1):15-27 [PMID: 19601392]
  3. Indian Heart J. 2004 Nov-Dec;56(6):646-52 [PMID: 15751521]
  4. Pak J Pharm Sci. 2012 Apr;25(2):333-7 [PMID: 22459457]
  5. J Ethnopharmacol. 2006 Jul 19;106(3):321-6 [PMID: 16567073]
  6. Exp Toxicol Pathol. 2011 Mar;63(3):285-90 [PMID: 20163942]
  7. Curr Atheroscler Rep. 2007 Nov;9(5):367-74 [PMID: 18001619]
  8. Bull World Health Organ. 2006 Jun;84(6):461-9 [PMID: 16799730]
  9. Life Sci. 2006 Jan 2;78(6):655-63 [PMID: 16165163]
  10. Saudi Med J. 2011 Jul;32(7):695-700 [PMID: 21748206]
  11. J Biol Chem. 1997 Aug 22;272(34):20963-6 [PMID: 9261091]
  12. J Atheroscler Thromb. 2005;12(2):111-9 [PMID: 15942122]
  13. Pharmazie. 2004 Jul;59(7):561-4 [PMID: 15296096]

Word Cloud

Created with Highcharts 10.0.0mg/dlP0Group5±<totalcholesterolpatients001decreasedsignificantlyformulationclinicalpost-treatmentreceivedsafoof-e-muhazzil37treatmentmeanpercentagechangerelieffatiguepalpitationdyspnea01studyUnanihyperlipidemiabiochemicalparameterslevelthirty243294SMclassicalform23482224256310standardwellBC2620unaniAIMOFTHESTUDY:aimfollowingevaluateefficacytolerabilitycompoundMATERIALSANDMETHODS:90220included'A'powdergtwicedailyorally'B'compressedtabletdosage'C'30atorvastatinmgcontrolFollow-upcarriedsecondfourth6thweekevaluatedRESULTS:225695335%reduced2126794911%Control1787346693%significant72%1609%>17%1814%2291%46%non-significantincrease22%observed22%non-significantly1764%ResultsindicatetestdrugsafelyeffectivelyamelioratesconditiondecreasingEvaluationpharmacopeialhyperlipidemia:randomizedcontrolledHyperlipidemia

Similar Articles

Cited By